ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway

International Journal of Cancer

Volumn 136, Issue 11, 2015, Pages 2598-2609

  Lo Iacono, Marco ^a   Monica, Valentina ^a   Vavalà, Tiziana ^a   Gisabella, Mara ^a   Saviozzi, Silvia ^a   Bracco, Enrico ^a   Novello, Silvia ^a   Papotti, Mauro ^a   Scagliotti, Giorgio Vittorio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

ATF2; celastrol; cisplatin resistance; non small cell lung cancer

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; CELASTROL; CISPLATIN; MESSENGER RNA; STRESS ACTIVATED PROTEIN KINASE; ATF2 PROTEIN, HUMAN; TRIPTERINE; TRITERPENE;

ADULT; AGED; ARTICLE; ATF2 GENE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; VERY ELDERLY;

ACTIVATING TRANSCRIPTION FACTOR 2; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; PROGNOSIS; TRITERPENES;

EID: 84924860249     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29302     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
3. Schuette WH, Groschel A, Sebastian M, et al. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer 2013; 14: 215-23.
4. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-53.
5. Gupta S, Campbell D, Derijard B, et al. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995; 267: 389-93.
6. Livingstone C, Patel G, Jones N,. ATF-2 contains a phosphorylation-dependent transcriptional activation domain. EMBO J 1995; 14: 1785-97.
7. Vlahopoulos SA, Logotheti S, Mikas D, et al. The role of ATF-2 in oncogenesis. Bioessays 2008; 30: 314-27.
8. Hayakawa J, Depatie C, Ohmichi M, et al. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J Biol Chem 2003; 278: 20582-92.
9. van Dam H, Castellazzi M,. Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene 2001; 20: 2453-64.
10. Berger AJ, Kluger HM, Li N, et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 2003; 63: 8103-7.
11. Tao X, Younger J, Fan FZ, et al. Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2002; 46: 1735-43.
12. Kim DY, Park JW, Jeoung D, et al. Celastrol suppresses allergen-induced airway inflammation in a mouse allergic asthma model. Eur J Pharmacol 2009; 612: 98-105.
13. Qiu D, Kao PN,. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D 2003; 4: 1-18.
14. Nagase M, Oto J, Sugiyama S, et al. Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem 2003; 67: 1883-7.
15. Abbas S, Bhoumik A, Dahl R, et al. Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin Cancer Res 2007; 13: 6769-78.
16. Zhang T, Hamza A, Cao X, et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008; 7: 162-70.
17. Ge P, Ji X, Ding Y, et al. Celastrol causes apoptosis and cell cycle arrest in rat glioma cells. Neurol Res 2010; 32: 94-100.
18. Lu Z, Jin Y, Qiu L, et al. Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett 2010; 290: 182-91.
19. Mou H, Zheng Y, Zhao P, et al. Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways. Toxicology In Vitro 2011; 25: 1027-32.
20. Huang Y, Zhou Y, Fan Y, et al. Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett. 2008; 264: 101-6.
21. Yang H, Chen D, Cui QC, et al. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006; 66: 4758-65.
22. He D, Xu Q, Yan M, et al. The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 2009; 9: 343.
23. Zhu H, Ding WJ, Wu R, et al. Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol. Cancer Invest 2010; 28: 23-32.
24. Dai Y, DeSano JT, Meng Y, et al. Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74: 1217-25.
25. Jung HW, Chung YS, Kim YS, et al. Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells. Exp Mol Med 2007; 39: 715-21.
26. Zhou YX, Huang YL,. Antiangiogenic effect of celastrol on the growth of human glioma: an in vitro and in vivo study. Chin Med J 2009; 122: 1666-73.
27. Bai JP, Shi YL, Fang X, et al. Effects of demethylzeylasteral and celastrol on spermatogenic cell Ca2+ channels and progesterone-induced sperm acrosome reaction. Eur J Pharmacol 2003; 464: 9-15.
28. Sun HY, Liu XD, Xiong QJ, et al. Chronic inhibition of cardiac Kir2.1 and hERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking. J Biol Chem 2006; 281: 5877-84.
29. Raja SM, Clubb RJ, Ortega-Cava C, et al. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther 2011; 11: 263-76.
30. Yuan Z, Gong S, Luo J, et al. Opposing roles for ATF2 and c-Fos in c-Jun-mediated neuronal apoptosis. Mol Cell Biol 2009; 29: 2431-42.
31. Travis WD, Brambilla E, Müller-Hermelink HK, et al. World Health Organization classification of tumors: pathology and genetics of tumors of the lung, pleura, thymus and hearted. Lyon: IARC Press, 2004.
32. Guo YL, Kang B, Williamson JR,. Inhibition of the expression of mitogen-activated protein phosphatase-1 potentiates apoptosis induced by tumor necrosis factor-alpha in rat mesangial cells. J Biol Chem 1998; 273: 10362-6.
33. Ronai Z, Yang YM, Fuchs SY, et al. ATF2 confers radiation resistance to human melanoma cells. Oncogene 1998; 16: 523-31.
34. Bhoumik A, Huang TG, Ivanov V, et al. An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest 2002; 110: 643-50.
35. Shah M, Bhoumik A, Goel V, et al. A role for ATF2 in regulating MITF and melanoma development. PLoS Genet 2010; 6: e1001258.
36. Hayakawa J, Mittal S, Wang Y, et al. Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol Cell 2004; 16: 521-35.
37. Johnson GL, Nakamura K,. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta 2007; 1773: 1341-8.
38. Kyriakis JM, Avruch J,. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81: 807-69.
39. Potapova O, Haghighi A, Bost F, et al. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 1997; 272: 14041-4.
40. Bhoumik A, Gangi L, Ronai Z,. Inhibition of melanoma growth and metastasis by ATF2-derived peptides. Cancer Res 2004; 64: 8222-30.
41. Salameh A, Galvagni F, Anselmi F, et al. Growth factor stimulation induces cell survival by c-Jun. ATF2-dependent activation of Bcl-XL. J Biol Chem 2010; 285: 23096-104.
42. Saviozzi S, Ceppi P, Novello S, et al. Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. Cancer Res 2009; 69: 3390-6.
43. Ceppi P, Novello S, Cambieri A, et al. Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2009; 15: 1039-45.
44. Lo Iacono M, Monica V, Saviozzi S, et al. Aurora kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation. J Transl Med 2011; 9: 100.
45. Mortaz E, Kraneveld AD, Smit JJ, et al. Effect of cigarette smoke extract on dendritic cells and their impact on T-cell proliferation. PLoS ONE 2009; 4: e4946.
46. Ranganna K, Yousefipour Z, Nasif R, et al. Acrolein activates mitogen-activated protein kinase signal transduction pathways in rat vascular smooth muscle cells. Mol Cell Biochem 2002; 240: 83-98.
47. Vikman P, Xu CB, Edvinsson L,. Lipid-soluble cigarette smoking particles induce expression of inflammatory and extracellular-matrix-related genes in rat cerebral arteries. Vasc Health Risk Manag 2009; 5: 333-41.
48. Kasibhatla S, Brunner T, Genestier L, et al. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1998; 1: 543-51.
49. Wang TH, Wang HS, Ichijo H, et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 1998; 273: 4928-36.